JP2002513422A5 - - Google Patents

Download PDF

Info

Publication number
JP2002513422A5
JP2002513422A5 JP1999505301A JP50530199A JP2002513422A5 JP 2002513422 A5 JP2002513422 A5 JP 2002513422A5 JP 1999505301 A JP1999505301 A JP 1999505301A JP 50530199 A JP50530199 A JP 50530199A JP 2002513422 A5 JP2002513422 A5 JP 2002513422A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1999505301A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002513422A (ja
Filing date
Publication date
Priority claimed from GBGB9713739.2A external-priority patent/GB9713739D0/en
Application filed filed Critical
Publication of JP2002513422A publication Critical patent/JP2002513422A/ja
Publication of JP2002513422A5 publication Critical patent/JP2002513422A5/ja
Ceased legal-status Critical Current

Links

JP50530199A 1997-06-27 1998-06-26 新規甲状腺レセプターリガンドおよび方法 Ceased JP2002513422A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9713739.2 1997-06-27
GBGB9713739.2A GB9713739D0 (en) 1997-06-27 1997-06-27 Thyroid receptor ligands
PCT/EP1998/004039 WO1999000353A1 (en) 1997-06-27 1998-06-26 Novel thyroid receptor ligands and method

Publications (2)

Publication Number Publication Date
JP2002513422A JP2002513422A (ja) 2002-05-08
JP2002513422A5 true JP2002513422A5 (enExample) 2005-12-02

Family

ID=10815109

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50530199A Ceased JP2002513422A (ja) 1997-06-27 1998-06-26 新規甲状腺レセプターリガンドおよび方法

Country Status (13)

Country Link
US (1) US6465687B1 (enExample)
EP (1) EP1000008B1 (enExample)
JP (1) JP2002513422A (enExample)
KR (1) KR20010020472A (enExample)
AT (1) ATE243672T1 (enExample)
AU (1) AU735525C (enExample)
CA (1) CA2294098C (enExample)
DE (1) DE69815852T2 (enExample)
DK (1) DK1000008T3 (enExample)
ES (1) ES2197486T3 (enExample)
GB (1) GB9713739D0 (enExample)
PT (1) PT1000008E (enExample)
WO (1) WO1999000353A1 (enExample)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380255B1 (en) * 1995-06-07 2002-04-30 Karo Bio Ab Treatment for dermal skin atrophy using thyroid hormone compounds or thyroid hormone-like compounds
EP1127882A1 (en) 2000-01-25 2001-08-29 Pfizer Products Inc. Tetrazole compounds as thyroid receptor ligands
PT1257526E (pt) * 2000-02-17 2005-09-30 Bristol Myers Squibb Co Ligandos derivados de anilina para o receptor de tiroide
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6620830B2 (en) 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
ES2248242T3 (es) * 2000-04-21 2006-03-16 Pfizer Products Inc. Ligandos de receptores tiroideos.
US6395784B1 (en) * 2000-06-07 2002-05-28 Bristol-Myers Squibb Company Benzamide ligands for the thyroid receptor
DE10038007A1 (de) 2000-08-04 2002-02-14 Bayer Ag Neue Amino-und Amido-Diphenylether für Arzneimittel
AU2002237298B2 (en) * 2001-02-08 2006-08-03 Karo Bio Ab Phenoxy substituted benzocondensed heteroaryl derivatives as thyroid receptor ligands
US6777442B2 (en) 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
US6423549B1 (en) * 2001-03-14 2002-07-23 Bio-Rad Laboratories, Inc. Phycoerythrin labeled thyronine analogues and assays using labeled analogues
ATE318272T1 (de) 2001-04-11 2006-03-15 Bristol Myers Squibb Co Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
GB0111861D0 (en) * 2001-05-15 2001-07-04 Karobio Ab Novel compounds
US7279593B2 (en) 2001-08-24 2007-10-09 Karo Bio Ab Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
HUP0700151A2 (en) 2001-10-18 2007-05-29 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US6984645B2 (en) 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US6831102B2 (en) 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
GB0208384D0 (en) * 2002-04-11 2002-05-22 Karobio Ab Novel compounds
WO2003094845A2 (en) 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
ATE469645T1 (de) 2002-10-23 2010-06-15 Bristol Myers Squibb Co Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
AU2003302084A1 (en) 2002-11-15 2004-06-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
WO2004066929A2 (en) * 2003-01-24 2004-08-12 Bristol-Myers Squibb Company Cycloalkyl containing anilide ligands for the thyroid receptor
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7557143B2 (en) 2003-04-18 2009-07-07 Bristol-Myers Squibb Company Thyroid receptor ligands
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7674913B2 (en) 2003-11-12 2010-03-09 Phenomix Corporation Heterocyclic boronic acid compounds
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
WO2006128055A2 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US7829552B2 (en) * 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
US7145040B2 (en) 2004-07-02 2006-12-05 Bristol-Myers Squibb Co. Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
WO2006017292A1 (en) 2004-07-12 2006-02-16 Phenomix Corporation Constrained cyano compounds
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
US7691898B2 (en) 2004-10-08 2010-04-06 Kotobuki Pharmaceutical Co., Ltd. Phosphonic acid derivatives and the treating agents of diseases related hyperphosphatemia
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7635699B2 (en) 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7589088B2 (en) 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
WO2006076597A1 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7361766B2 (en) 2005-01-12 2008-04-22 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7314882B2 (en) 2005-01-12 2008-01-01 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2006078697A1 (en) 2005-01-18 2006-07-27 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006086464A2 (en) 2005-02-10 2006-08-17 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
EP2527337A1 (en) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
MX2007014501A (es) * 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos novedosos que contienen acido fosfinico.
JP2008542301A (ja) 2005-05-26 2008-11-27 メタバシス・セラピューティクス・インコーポレイテッド 脂肪性肝疾患の処置のための甲状腺ホルモン様薬剤
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
CA2614529C (en) * 2005-07-21 2011-06-28 F. Hoffmann-La Roche Ag Pyridazinone derivatives as thyroid hormone receptor agonists
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
US7488725B2 (en) 2005-10-31 2009-02-10 Bristol-Myers Squibb Co. Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
EP2021014A1 (en) 2006-05-26 2009-02-11 Brystol-Myers Squibb Company Sustained release glp-1 receptor modulators
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
EP2666777A1 (en) 2006-08-02 2013-11-27 Cytokinetics, Inc. Certain chemical entities having an imidazo<4,5-b>pyrazin-2(3H)-one core, compositions and methods
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7968577B2 (en) 2006-11-01 2011-06-28 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
JP2010508358A (ja) 2006-11-01 2010-03-18 ブリストル−マイヤーズ スクイブ カンパニー グルココルチコイド受容体、ＡＰ−１、および／またはＮＦ−κＢ活性の調節剤、並びにその使用
TW200904405A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
JP2010524953A (ja) 2007-04-17 2010-07-22 ブリストル−マイヤーズ スクイブ カンパニー 縮合ヘテロ環１１−β−ヒドロキシステロイドデヒドロゲナーゼＩ型阻害剤
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
CN101808995A (zh) 2007-07-27 2010-08-18 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
US8076334B2 (en) 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
AU2008302570B2 (en) 2007-09-20 2012-05-31 Irm Llc Compounds and compositions as modulators of GPR119 activity
EP2209780B1 (en) 2007-11-01 2014-01-01 Bristol-Myers Squibb Company Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf- kappa b activity and use thereof
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2756786A1 (en) 2009-03-27 2010-09-30 Bristol-Myers Squibb Company Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
AU2010303780B2 (en) 2009-10-09 2014-02-20 Irm Llc Compounds and compositions as modulators of GPR119 activity
CN102740839B (zh) 2009-11-13 2015-05-06 阿斯利康(瑞典)有限公司 立即释放片剂
CN105193761B (zh) 2009-11-13 2019-12-06 阿斯利康(瑞典)有限公司 双层片剂
US20120294936A1 (en) 2009-11-13 2012-11-22 Astrazeneca Uk Limited Reduced mass metformin formulations
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
ES2559209T3 (es) 2010-04-14 2016-02-11 Bristol-Myers Squibb Company Nuevos activadores de la glucocinasa y métodos de uso de los mismos
WO2011133920A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
TWI631963B (zh) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
EP2892897A1 (en) 2012-09-05 2015-07-15 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
WO2014039411A1 (en) 2012-09-05 2014-03-13 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
UA117574C2 (uk) 2012-11-20 2018-08-27 Лексікон Фармасьютікалз, Інк. Інгібітори котранспортера натрій-глюкози 1
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
ES2924479T3 (es) 2013-04-08 2022-10-07 Harvard College Composiciones para rejuvenecer las células madre del músculo esquelético
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
US9593113B2 (en) 2013-08-22 2017-03-14 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
WO2017180988A2 (en) 2016-04-15 2017-10-19 Indiana University Research And Technology Corporation Fgf21 c-terminal peptide optimization
CN113277958A (zh) * 2016-05-18 2021-08-20 俄勒冈健康科学大学 苏比替罗衍生物
EP3541395A4 (en) 2016-11-21 2020-07-01 Viking Therapeutics, Inc. GLYCOGENOSIS TREATMENT METHODS
EP3634426A4 (en) 2017-06-05 2021-04-07 Viking Therapeutics, Inc. COMPOSITIONS FOR TREATMENT OF FIBROSE
WO2019119673A1 (zh) 2017-12-19 2019-06-27 北京吉源生物科技有限公司 一种双基因修饰的干细胞及其用途
CA3094167A1 (en) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
WO2020016335A1 (en) 2018-07-19 2020-01-23 Astrazeneca Ab Methods of treating hfpef employing dapagliflozin and compositions comprising the same
EP3842410A4 (en) 2018-08-23 2022-07-06 Qingdao Wholesometech Co., Ltd. Fibric acid compound and medical use thereof
KR20210065974A (ko) 2018-09-26 2021-06-04 렉시컨 파마슈티컬스 인코퍼레이티드 N-(1-((2-(디메틸아미노)에틸)아미노)-2-메틸-1-옥소프로판-2-일)-4-(4-(2-메틸-5-((2s,3r,4r,5s,6r)-3,4,5-트리히드록시-6-(메틸티오)테트라히드로-2h-피란-2-일)벤질)페닐)부탄아미드의 결정질 형태 및 그의 합성 방법
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
JP2022513449A (ja) * 2018-12-12 2022-02-08 オートバーン セラピューティクス，インク． 新規な甲状腺模倣物
EP3931180A1 (en) 2019-03-01 2022-01-05 Autobahn Therapeutics, Inc. Novel thyromimetics
WO2020264358A1 (en) 2019-06-27 2020-12-30 Cytokinetics, Inc. Polymorphs of 1-(2-((((trans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methyl)amino)pyrimidin-5-yl)-1h-pyrrole-3-carboxamide
IL293389B1 (en) 2019-11-29 2025-12-01 Autobahn Therapeutics Inc Novel thyromimetics
US12528761B2 (en) 2020-06-17 2026-01-20 Autobahn Therapeutics, Inc. Thyromimetics

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1072998B (de) * 1957-08-21 1960-01-14 Farbwerke Hoechst Aktiengesellschaft vormals Meister Lucius &. Brüning, Frankfurt/M Verfahren zur Herstellung von substituierten Diphenyläthern
DE1078582B (de) * 1958-10-29 1960-03-31 Hoechst Ag Verfahren zur Herstellung substituierter Thyropropionsaeuren

Similar Documents

Publication Publication Date Title
JP2000509635A5 (enExample)
JP2000509942A5 (enExample)
JP2000507042A5 (enExample)
JP2000510751A5 (enExample)
JP2000509912A5 (enExample)
JP2000509637A5 (enExample)
JP2001521560A5 (enExample)
JP2000509587A5 (enExample)
JP2000507369A5 (enExample)
JP2002503335A5 (enExample)
JP2000507433A5 (enExample)
JP2000508866A5 (enExample)
JP2000510793A5 (enExample)
JP2000508022A5 (enExample)
JP2000508841A5 (enExample)
JP2000508680A5 (enExample)
JP2000509804A5 (enExample)
JP2000509853A5 (enExample)
JP2000509755A5 (enExample)
JP2000510247A5 (enExample)
JP2000510969A5 (enExample)
JP2000508836A5 (enExample)
JP2000508102A5 (enExample)
JP2000509818A5 (enExample)
JP2000509520A5 (enExample)